Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two groundbreaking trials have this year reported conflicting results as to the benefit of screening for prostate cancer. Careful interpretation in the light of contemporary data is needed to reveal the value of this intervention.

Original publication

DOI

10.1038/nrurol.2009.95

Type

Journal article

Journal

Nat Rev Urol

Publication Date

06/2009

Volume

6

Pages

301 - 303

Keywords

Adult, Aged, Biomarkers, Tumor, Humans, Male, Mass Screening, Middle Aged, Prostate-Specific Antigen, Prostatic Neoplasms, Randomized Controlled Trials as Topic